Company Performance - Masimo reported quarterly earnings of $1.33 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and up from $0.86 per share a year ago, representing an earnings surprise of +8.13% [1] - The company posted revenues of $370.9 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.59%, but down from $496.3 million year-over-year [2] - Over the last four quarters, Masimo has consistently surpassed consensus EPS estimates and revenue estimates [2] Future Outlook - The immediate price movement of Masimo's stock will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $1.14 on revenues of $369.36 million, and for the current fiscal year, it is $4.98 on revenues of $1.52 billion [7] - The estimate revisions trend for Masimo was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Masimo belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance compared to higher-ranked industries [8] - The performance of Masimo's stock may also be influenced by the overall outlook for the industry [8]

Core Viewpoint - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.62 per share a year ago [1][2] Financial Performance - The company achieved revenues of $82.28 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26% and showing an increase from $78.03 million in the same quarter last year [3] - Inogen has surpassed consensus EPS estimates in all four of the last quarters [2][3] Stock Performance - Inogen shares have declined approximately 22.9% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current Zacks Rank for Inogen is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $91.8 million, and for the current fiscal year, it is -$1.41 on revenues of $352.81 million [8] - The trend of estimate revisions for Inogen is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

Core Viewpoint - Mettler-Toledo reported quarterly earnings of $8.19 per share, exceeding the Zacks Consensus Estimate of $7.90, but down from $8.89 per share a year ago, indicating a 7.9% year-over-year decline in earnings [1][2] Financial Performance - The company achieved revenues of $883.74 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $925.95 million in the same quarter last year, reflecting a year-over-year revenue decline of 4.6% [2] - Mettler-Toledo has consistently surpassed consensus EPS estimates over the last four quarters, achieving an earnings surprise of 3.67% in the latest report [1][2] Stock Performance - Mettler-Toledo shares have declined approximately 12.5% since the beginning of the year, compared to a 5.3% decline in the S&P 500 [3] - The current Zacks Rank for Mettler-Toledo is 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $10.22, with expected revenues of $957.72 million, while the estimate for the current fiscal year is $42.51 on revenues of $3.91 billion [7] - The trend of estimate revisions for Mettler-Toledo is currently mixed, which may change following the latest earnings report [6] Industry Context - The Medical - Instruments industry, to which Mettler-Toledo belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]